What is urethral cancer?
Urethral cancer is a rare cancer of the urethra, the narrow passage through which urine leaves the body after it is released from the bladder. In women the urethra is short, about 4 cm, and opens just above the vagina. In men it is much longer, running through the prostate and along the penis.
When the cancer starts in the urethra itself, doctors call it primary urethral carcinoma. This is different from bladder cancer that later spreads into the urethra, which is more common. Primary urethral cancer makes up far less than 1% of all cancers (Gakis et al., 2013), so most hospitals see only a few cases each year.
Several kinds of cell line the urethra, and each can give rise to a different type of cancer. The main ones are urothelial carcinoma, squamous cell carcinoma and adenocarcinoma. The type found most often depends on the person’s sex and on which part of the urethra is affected.
The disease is most common in people over 60. Early symptoms such as blood in the urine, a weak stream or a lump can be mistaken for infection or a narrowing of the urethra. Treatment depends on the stage, position and type of cancer and on whether the person is male or female. It may involve surgery, radiotherapy and chemotherapy, often in combination (Janisch et al., 2019).
1. Key facts at a glance
| Feature | Details |
|---|---|
| What it is | Cancer that starts in the lining of the urethra |
| How common | Very rare; well under 1% of cancers |
| Typical age | Usually over 60 |
| Who is affected | Both sexes; types and treatment differ between men and women |
| Main types | Urothelial carcinoma, squamous cell carcinoma, adenocarcinoma |
| Common symptoms | Blood in the urine, difficulty passing urine, a lump or discharge |
| Key imaging test | MRI of the pelvis |
| Main treatments | Surgery, radiotherapy and platinum-based chemotherapy |
| Outlook | Good for small, early tumours; poorer when advanced |
2. Types of urethral cancer
By cell type
| Type | Where it usually arises | Notes |
|---|---|---|
| Urothelial (transitional cell) carcinoma | The prostatic and posterior urethra in men; the part near the bladder in women | Often linked with bladder cancer |
| Squamous cell carcinoma | The front part of the urethra in men; the outer urethra in women | Linked with chronic irritation and HPV |
| Adenocarcinoma | Glands around the urethra, especially in women | Includes clear cell and Skene gland types |
| Rare types | Melanoma, sarcoma, neuroendocrine carcinoma | Very uncommon |
In women, adenocarcinoma is now reported as the most common type (Lagarde-Lenon and Aron, 2022).
By position
| Part of the urethra | Men | Women | Lymph node drainage |
|---|---|---|---|
| Anterior (front, distal) | Penile urethra | Outer third | Groin (inguinal) nodes |
| Posterior (back, proximal) | Bulbar and prostatic urethra | Inner two-thirds | Pelvic nodes |
Cancers near the opening tend to be found earlier and do better than those deeper inside.
Urethral cancer after bladder removal
People who have had the bladder removed for bladder cancer, but kept the urethra, can later develop cancer in the remaining urethra. This is called secondary urethral cancer and is checked for during bladder cancer follow-up.
3. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Older age | Risk rises after 60 |
| Chronic inflammation | Repeated infections or long-term catheter use |
| Urethral stricture | Narrowing from scarring, especially in men |
| Sexually transmitted infections | Including human papillomavirus (HPV) |
| Urethral diverticulum | A pouch off the urethra in women; can harbour adenocarcinoma |
| Previous bladder cancer | Linked to urothelial carcinoma of the urethra |
| Previous pelvic radiotherapy | Small increase in risk |
| Smoking | Increases the risk of urothelial cancers |
A population study of 453 people found differences between the sexes in tumour type and stage. For example, women were more likely to have adenocarcinoma and men more likely to have squamous or urothelial types (Wei et al., 2017).
4. How does it look
On examination
| Feature | Description |
|---|---|
| At the urethral opening | A red, raised, wart-like or ulcerated growth |
| Along the penis | A firm lump felt along the underside |
| In women | A mass at or around the urethral opening, or felt through the vaginal wall |
| Groin | Enlarged, firm lymph nodes in advanced cases |
On cystoscopy
Looking inside with a cystoscope may show a papillary (frond-like) growth, a flat red patch, or an area of narrowing that bleeds easily.
On MRI
MRI of the pelvis is the preferred test to judge how far the tumour has grown into surrounding tissue (Gakis et al., 2013). It shows the tumour’s depth and its relationship to the penis, prostate, vagina, bladder neck and pelvic floor.
Under the microscope
| Type | Appearance |
|---|---|
| Urothelial carcinoma | Cells like bladder lining, in sheets or papillary fronds |
| Squamous cell carcinoma | Flattened cells, often with keratin |
| Adenocarcinoma | Gland-forming cells; clear cell type has pale cytoplasm |
5. Symptoms
Common symptoms
- Blood in the urine or blood from the urethra
- Difficulty passing urine, a weak or split stream
- Needing to pass urine often or urgently
- Pain or burning when passing urine
- A lump or thickening along the urethra or penis
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Discharge from the urethra | Tumour or associated infection |
| Swollen glands in the groin | Spread to inguinal lymph nodes |
| Pain during sex | Tumour near the vagina or penis |
| Inability to pass urine | Complete blockage |
| A fistula | Abnormal opening between the urethra and skin or vagina |
When to seek medical advice
See a doctor if you notice blood in your urine, a new lump on the penis or around the urethral opening, or urinary symptoms that do not settle with treatment for infection. These are much more often caused by other conditions, but they should be checked.
6. Diagnosis
| Test | Purpose |
|---|---|
| Physical examination | Including the genitals, groin nodes and, in women, a pelvic examination |
| Urine tests | Infection and abnormal cells |
| Urethrocystoscopy | Looks directly at the urethra and bladder |
| Biopsy | Confirms the cancer and its type |
| MRI of the pelvis | Shows local extent |
| CT of the chest, abdomen and pelvis | Checks lymph nodes and distant spread |
| Fine needle aspiration of groin nodes | If nodes are enlarged |
Other cancers can look the same under the microscope, so doctors also check for bladder, prostate, cervical, vulval or bowel cancers that may have spread to the urethra.
Staging
Urethral cancer is staged using the TNM system.
| Component | What it describes |
|---|---|
| T (tumour) | Depth: lining only, into supporting tissue, into the spongy tissue of the penis or the prostate, or into nearby organs |
| N (nodes) | Spread to groin or pelvic lymph nodes |
| M (metastasis) | Spread to distant organs such as the lungs, liver or bone |
7. Treatment
A specialist multidisciplinary team should plan care, including urologists, radiation oncologists and medical oncologists.
Early-stage cancer
| Situation | Treatment options |
|---|---|
| Small tumour at the front of the urethra (men) | Organ-sparing surgery, removing the tumour or part of the urethra and keeping the penis |
| Small tumour in women | Local excision or radiotherapy for tumours at the opening; complete removal of the urethra is often advised to lower the risk of positive margins |
| Non-invasive urothelial cancer of the prostatic urethra | Endoscopic removal (transurethral resection) plus BCG treatment |
| Small tumour in people who decline surgery | Radiotherapy, including brachytherapy |
Organ-sparing surgery is reasonable when clear margins can be achieved (Gakis et al., 2013). A review found that radiotherapy alone generally gave poorer control than surgery in localised disease (Janisch et al., 2019).
Locally advanced cancer
| Approach | Notes |
|---|---|
| Chemotherapy before surgery | Platinum-based combinations can improve survival |
| Radical surgery | May include removal of the urethra, bladder and prostate in men, or the urethra, bladder and part of the vagina in women |
| Chemoradiotherapy | Radiotherapy with chemotherapy, particularly for squamous cell carcinoma |
| Lymph node dissection | Removes groin or pelvic nodes |
Combining treatments works better than any single treatment for advanced tumours (Janisch et al., 2019).
Chemotherapy choices by cell type
| Cell type | Typical regimens |
|---|---|
| Urothelial carcinoma | Cisplatin combinations such as gemcitabine-cisplatin |
| Squamous cell carcinoma | Cisplatin with 5-FU, often with radiotherapy |
| Adenocarcinoma | Regimens similar to those used for bowel or gynaecological cancers |
Spread to distant organs
Treatment aims to control the cancer and symptoms. Options include chemotherapy, immunotherapy with checkpoint inhibitors and, for urothelial cancer, newer drugs such as enfortumab vedotin. Clinical trials are encouraged.
Urine diversion after surgery
| Option | Description |
|---|---|
| Perineal urethrostomy | Urine passes through a new opening behind the scrotum; men then sit to pass urine |
| Ileal conduit | Urine drains through a stoma into a bag |
| Continent diversion | An internal pouch emptied with a catheter |
| Neobladder | A new bladder made from bowel, in selected people |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Changes to urination, sexual function and body image |
| Radiotherapy | Urethral narrowing, bladder irritation, skin soreness, vaginal dryness |
| Chemotherapy | Tiredness, nausea, infection risk, kidney or hearing effects with cisplatin |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Local excision | Often a short hospital stay; a catheter for several days |
| Radical surgery | About 1-2 weeks in hospital; weeks of recovery at home |
| Radiotherapy | Weekday sessions for around 5-7 weeks, or a short hospital stay for brachytherapy |
| Chemotherapy | Usually 3-4 cycles before surgery, each lasting 3 weeks |
8. Outlook (prognosis)
The outlook depends mainly on stage. Small tumours near the opening can often be cured. Cancers that have grown deep or reached lymph nodes are harder to treat.
| Factor | Effect on outlook |
|---|---|
| Low stage | Good outlook |
| Anterior (front) position | Better than posterior |
| Lymph node involvement | Poorer survival |
| Distant spread | Poor outlook |
| Older age | Shorter overall survival |
| Treatment with surgery | Linked with longer survival in women in one population study (Wei et al., 2017) |
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review and examination every 3-6 months | Checks for local recurrence |
| Cystoscopy or urethroscopy | Looks at the remaining urethra and bladder |
| Urine cytology | For urothelial cancers |
| MRI or CT | Checks the pelvis, nodes and lungs |
| Groin examination | For nodal recurrence |
10. Living with urethral cancer
- Learn how to care for a stoma or catheter if you have one; specialist nurses can help
- Drink enough fluids to keep urine flowing
- Report bleeding, infection or a weak stream promptly
- Ask about sexual health support; changes after treatment are common and help is available
- Do pelvic floor exercises if advised
- Stop smoking to reduce the risk of further urothelial cancers
- Seek support from urology cancer charities and counselling services
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as bladder cancer? | No, though urothelial urethral cancer is related and they can occur together |
| Is it caused by HPV? | Some squamous cell carcinomas are linked to HPV |
| Will I still be able to have sex? | Often yes after organ-sparing treatment; more radical surgery can affect sexual function |
| Will I need a urine bag? | Not always; it depends on the operation |
| Can radiotherapy be used instead of surgery? | For some small tumours, especially in women |
| Is it more common in men or women? | It occurs in both; types and treatments differ |
| Can it come back? | Yes, so regular follow-up is important |
12. Questions to ask your care team
- What type of urethral cancer do I have, and where exactly is it?
- What is the stage, and have the lymph nodes been checked?
- Is organ-sparing treatment possible?
- Would chemotherapy before surgery help me?
- How will treatment affect urination and sexual function?
- Who can help me if I need a stoma?
- How often will I need check-ups?
- Is this hospital experienced in treating urethral cancer?
- Are there any clinical trials I could join?
Resources
- Gakis, G. et al. (2013) ‘EAU guidelines on primary urethral carcinoma’, European Urology, 64(5), pp. 823-830.
- Janisch, F. et al. (2019) ‘Current disease management of primary urethral carcinoma’, European Urology Focus, 5(5), pp. 722-734.
- Lagarde-Lenon, M.S. and Aron, M. (2022) ‘Female urethral carcinoma: a contemporary review of the clinicopathologic features, with emphasis on the histoanatomic landmarks and potential staging issues’, Human Pathology, 129, pp. 71-80.
- Wei, Y. et al. (2017) ‘Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study’, OncoTargets and Therapy, 10, pp. 3381-3389.
- National Cancer Institute (2026) Urethral Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/urethral/hp/urethral-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.